ArticleCureus2025
Phantosmia and Benzodiazepine Withdrawal: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Olfactory hallucinations, known as phantosmia, involve the perception of smell without the presence of existing chemical stimuli and are usually described as unpleasant. Other than a single brief mention as one of the symptoms of benzodiazepine withdrawal, olfactory hallucinations are not specifically listed as a symptom of benzodiazepine withdrawal in the common literature. We report the case of an older female with no previous history of psychosis, taking clonazepam for anxiety for five years. She was instructed by her outpatient provider to stop clonazepam before her elective surgery. Due to fear of mixing oxycodone prescribed for postoperative pain, the patient did not resume taking clonazepam during the hospitalization after surgery. No education was provided about benzodiazepine withdrawal or its symptoms. After discharge, she continued to hold clonazepam and started to experience a series of symptoms, such as insomnia, increased sensitivity to smell, and hearing music in her ears. On the day of admission, 14 days after her last clonazepam, she presented with the perception of an unpleasant odor, which she described as "bad" and "evil." Clonazepam was restarted, and all symptoms promptly resolved. To the best of our knowledge, no such case has been reported before. This case illustrates a rare presentation of olfactory hallucinations most likely precipitated by benzodiazepine withdrawal that was completely reversed by restarting the medication. In addition, it emphasizes the importance of providers and patient education regarding safe benzodiazepine discontinuation and raising awareness that olfactory hallucinations may present as a symptom of benzodiazepine withdrawal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.